Abstract: The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumaotid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.
Abstract: The present invention provides integrin ?IIb?3 specific antibodies and peptides. The antibodies and peptides demonstrate little or no immunoreactivity with other integrins. Methods for inhibiting platelet aggregation using the antibodies and peptides are also provided.
Abstract: The present invention relates to a method of modulating repair of a wound. The method includes modulating expression and/or activity of Flightless I in cells involved in repair of the wound.
Type:
Grant
Filed:
October 25, 2006
Date of Patent:
November 5, 2013
Assignees:
Womens & Childrens Health Research Institute, Adelaide Research & Innovation Pty Ltd, The Australian National University
Inventors:
Allison June Cowin, Hugh Douglas Campbell, Barry Powell
Abstract: The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.
Type:
Grant
Filed:
April 22, 2010
Date of Patent:
October 29, 2013
Assignee:
Indiana University Research & Technology Corporation
Abstract: The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen and Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.
Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
Type:
Grant
Filed:
November 15, 2011
Date of Patent:
October 15, 2013
Assignee:
Biogen IDEC MA Inc.
Inventors:
Philip Gotwals, Antonin de Fougerolles, Roy Lobb, Victor E. Kotelianski
Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
Abstract: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (?5?1) or vitronectin (?v?3 and ?v?5 integrins) are disclosed. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.
Type:
Grant
Filed:
April 3, 2009
Date of Patent:
September 17, 2013
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Jennifer R. Cochran, Richard Kimura, Aron M. Levin
Abstract: The specific molecular basis of the interaction between talin and integrin ?3 has been defined. This specific interaction provides a new therapeutic target; agents that can disrupt this specific interaction should be useful therapeutic agents for a number of significant diseases and conditions including inflammation, heart disease, including myocardial infarction, and tumor metastasis. The present invention includes a chimeric peptide that has high affinity for talin, muteins of talin and integrin ?3 as well as screening methods for agents that can disrupt the interaction between talin and integrin ?3.
Type:
Grant
Filed:
January 14, 2008
Date of Patent:
September 10, 2013
Assignee:
The Regents of the University of California
Inventors:
Mark Ginsberg, Anthony William Partridge, Iain Campbell, Kate Louise Wegener
Abstract: The present invention shows that site-specific antibodies to the (Na++K+)-ATPase exert a potent biological effect in cardiac myocytes and demonstrates a key structural region of the enzyme that participates in the regulation of cardiac contractility. These results establish an important link between a biological action and a precise molecular structure of the (Na++K+)-ATPase. Furthermore, the antibody-induced positive inotropic effect is independent of inactivation of the enzyme may reveal a novel mode for (Na++K+)-ATPase to regulate cardiac function. The data provide new molecular insights into the structural and functional relationship of the ubiquitous (Na++K+)-ATPase.
Abstract: The present invention generally concerns the detection and/or treatment of aneurysm in a non-invasive manner. In particular cases, the invention concerns methods and compositions for localizing a labeled composition to the site of an aneurysm for its detection and, in further cases, treatment of the aneurysm. In specific cases, the composition targets a subendothelial component of the aneurysmal wall, such as a smooth muscle cell exposed at the luminal surface of the vessel. In further specific cases, the composition targets an integrin receptor or laminin.
Type:
Grant
Filed:
November 23, 2008
Date of Patent:
July 23, 2013
Assignee:
Lers Surgical, LLC
Inventors:
Lionel C. Sevrain, Sylvie Y. Verdier-Sevrain
Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
Type:
Grant
Filed:
May 2, 2012
Date of Patent:
July 23, 2013
Assignee:
Medarex, L.L.C.
Inventors:
Josephine M. Cardarelli, Amelia Nancy Black
Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.
Type:
Grant
Filed:
August 9, 2012
Date of Patent:
July 9, 2013
Assignee:
Philogen S.p.A.
Inventors:
Jascha-Nikolai Rybak, Christoph Rosli, Alessandra Villa, Giovanni Neri, Dario Neri
Abstract: An antibody specific for a chondroitin sulphate epitope is described, as is a hybridoma cell line which produces such an antibody. The antibody is useful in the diagnosis and treatment of connective tissue diseases, such as arthritis and sarcomas. Test kits and pharmaceutical compositions are also described.
Type:
Grant
Filed:
June 1, 2005
Date of Patent:
July 9, 2013
Assignees:
The National Research Council of Thailand, The Thailand Research Fund, Chiang Mai University of Thailand
Abstract: The present invention relates to the biotechnology and particularly with new products for use in human health. The present invention provides new specific monoclonal antibodies, which bind with high affinity sulfatides and sulfated proteoglycans. The anti sulfatides and anti sulfated proteoglycans antibodies disclosed in the present invention and described in the description, provide important diagnostic and therapeutic tools to act on pathological processes associated with the appearance of atherosclerotic plaques. Accordingly, the invention provides pharmaceutical compositions comprising MAbs of the invention or fragments thereof for the therapeutic and diagnostic use associated with cardiovascular diseases. Particularly, the present invention relates to the fragments derived from the MAbs that recognize sulfatides and sulfated proteoglycans, which can be used in the therapy or diagnosis of this pathology.
Type:
Grant
Filed:
May 3, 2010
Date of Patent:
June 25, 2013
Assignee:
Centro de Inmunologia Molecular
Inventors:
Cristina Mateo De Acosta Del Rio, Ana Maria Vazquez Lopez, Alejandro Lopez Requena, Yuniel Fernandez Marrero, Yosdel Soto Lopez, Victor Brito Navarro
Abstract: The present invention provides the novel anti-IRC85 monoclonal antibody specifically binding with IRC85 and it showed potent effect in removing the infected/phagocytosed bacteria from THP-I, a monocytic cell that expresses human IRC85 and is infected with Listeria monocytogenes or WR-tubercle bacillus. Accordingly, it can be useful as a medicament and health care food in the prevention and treatment of tuberculosis disease and enteritis disease.
Abstract: Provided are a novel means for regulating inflammatory reactions by regulating the signaling in inflammatory responses caused by non-homeostatic cell death, specifically an anti-inflammatory agent comprising a substance that inhibits the expression of Mincle or the interaction of Mincle and SAP130 or FcR?, a screening method for a substance that regulates inflammatory reactions, comprising contacting Mincle or a fragment containing an extracellular region thereof and SAP130 in the presence and absence of a test substance, and comparing the degrees of the interaction of Mincle or the fragment thereof and SAP130 under the two conditions, a method of detecting non-homeostatic cell death, comprising measuring the amount of SAP130 in a sample collected from a subject animal, and the like.
Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.
Type:
Grant
Filed:
March 21, 2011
Date of Patent:
May 14, 2013
Assignee:
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Abstract: The present application provides methods of purifying A? binding proteins having a Fc region, for example, anti-A? antibodies or antibody fusions, by adsorbing the A? binding protein to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impurities and subsequent recovery of the adsorbed A? binding protein. The present application also features methods of eluting the purified A? binding protein as well as the incorporation of the methods within a purification train. Kits comprising components for carrying out the methods and instructions for use are also provided.
Abstract: The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.